Cornelia Ciorciaro
, Director - Safety Science Group Medical, Roche

“Inspiring virtual meeting allowing efficient learning about the most recent advances in gene therapy immunogenicity while still having interactions with peers.”

Gerald Craig, Business Development Manager, Absorption Systems LP

“An important discussion on a topic pivotal for advancing gene therapies.”

Robert J Kubiak, Clinical Pharmacologist, AstraZeneca

“I learned a lot about the what, who & how of the AAV gene therapy field.”

“I got a lot out of the interactive and exciting scientific discussions after each session.”

Helene Haegel, Principal Scientist – Immunosafety, Roche

“Excellent overview of the current understanding of AAV immunogenicity and new directions to mitigate it.”

Martijn Moransard, Associate Director, AveXis Inc.

“Very informative and diverse.”

Mark Milton, Executive Director, Novartis

An easy way to hear great talks.”

Michele Stone, Vice President - Translational Development, Kriya Therapeutics

“It was great to have a conference focused on analytical challenges for testing immune markers and modulating immune responses to gene therapies.”

Annahita Keravala, Senior Vice President - Gene Therapy, Coda Biotherapeutics

“It was a very good meeting with great quality presentations.”

Michael Grosso, Global Head - Clinical Development & Specialty Medicine, Daiichi Tanker Co. Ltd.

Excellent presentations and discussions.”

Pierre Burguière, Director - Analytical Development & Nonclinical Research, GenSight Biologics

Very well organized virtual event.”